Skip to main content
. 2022 Mar 17;13:795972. doi: 10.3389/fimmu.2022.795972

Figure 2.

Figure 2

Radiologic and pathological response to nIT with Tislelizumab, and surgical specimens in two patients with MSI-H/dMMR LACRC (pCR). (A, D) Imaging: Pretreatment (R) VS After 6 cycles of nIT (L); (B, E) Surgical specimens: After 6 cycles of nIT (R/L); (C, F) Pathology: Pretreatment (R) VS After 6 cycles of nIT (L).